BioCryst Pharmaceuticals (BCRX) Q2 2024 earnings summary

Executive summary

• ORLADEYO delivered exceptional Q2 2024 performance, with net revenue up 34% year-over-year to $108.3 million, driving total revenues to $109.3 million and marking a turnaround to GAAP operating profit.

• Net loss narrowed to $12.7 million ($0.06 per share) from $75.3 million in Q2 2023, with adjusted net loss per share at $0.06.

• ORLADEYO remains the only oral, targeted preventative therapy for hereditary angioedema (HAE), with strong efficacy, high patient retention, and expanding global approvals, including recent authorizations in Brazil, Mexico, and Peru.

• Pipeline progress includes a planned regulatory filing for pediatric use in 2025 and advancement of new molecules for rare diseases.

• The company is committed to accelerating profitability, reducing reliance on capital markets, and expects to achieve positive cash flow and EPS without raising additional funds.

Financial highlights

• Q2 2024 total revenue reached $109.3 million, with $108.3 million from ORLADEYO, marking a 34% year-over-year increase.

• U.S. ORLADEYO sales were $95.9 million, ex-U.S. sales $12.4 million, up 51% year-over-year.

• Operating profit was $21.9 million excluding non-cash stock comp, and $8.8 million including it.

• Cash, cash equivalents, and investments totaled $338.1 million at June 30, 2024.

• Operating expenses (excluding non-cash stock comp) were $87.4 million, down from both Q1 2024 and Q2 2023.

Outlook and guidance

• 2024 ORLADEYO revenue guidance raised to $420–$435 million, with operating expenses expected at $365–$375 million.

• Company expects full-year 2024 operating profit (excluding non-cash stock comp), with positive EPS and cash flow targeted for 2026.

• Path to $1 billion in peak global revenue for ORLADEYO is increasingly clear, with a U.S. target of $800 million by 2029.

• No plans to raise additional funds or draw the remaining $150 million from Pharmakon.

• Financial resources as of June 30, 2024, are expected to fund operations for at least the next 12 months.